Skip to main content

Genocea to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.

Conferences:

Event:Longwood Healthcare Leaders Winter Webconference – Details
Topic 1:Innovation in Cell Therapy
Format:Panel
Date:Thursday, January 6, 2022
Time:1:30 PM ET
Topic 2:Making a Big Impact With Limited Resources
Format:
Date:
Time:
Panel
Thursday, January 6, 2022
5:10 PM ET

Event:

LifeSci Partners 11th Annual Corporate Access Event – Details

Topic 1:Innovative Approaches to Cell Therapy for Oncology
Format:Panel
Date:Friday, January 7, 2022
Time:8:30 AM ET
Topic 2:Cancer Vaccines: Promises, Promises … Has Their Day Come?
Format:
Date:
Time:
Panel
Friday, January 7, 2022
2:00 PM ET

Event:H.C. Wainwright BIOCONNECT Virtual Conference – Details
Topic:Corporate Update
Format:On demand presentation
Date:Monday, January 10, 2022
Time:7:00 AM ET

Event:Advanced Therapies Week – Details
Topic:Add It Up: 3 Things to Consider for Capacity Expansion
Format:Panel
Date:Wednesday, January 26, 2022
Time:5:00 PM ET

About Genocea Biosciences, Inc.
Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, InhibigensTM, that drive pro-tumor immune responses. We have two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our adoptive T cell therapy comprising neoantigen-targeted peripheral cells for which we are conducting a Phase 1/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit https://www.genocea.com.

Investor Contact:  Media Contact:
Dan Ferry  Sarah O’Connell
617-430-7576  soconnell@vergescientific.com 
daniel@lifesciadvisors.com    

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.